Pseudomembranous Colitis following Bortezomib Therapy in a Myeloma Patient

The proteasome inhibitor, bortezomib, has antimyeloma activity even in myeloma cells refractory to multiple prior treatments. The most commonly reported adverse events in patients receiving bortezomib